Progress in the Development of the Products Portfolio and the R&D Pipeline
September 3, 2024
September 3, 2024
Participation terms in the Combined General Meeting
August 26, 2024
August 26, 2024
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
July 1, 2024
July 1, 2024
H.C. Wainwright & Co. Initiates MedinCell’s Coverage with a “Buy” Recommendation
June 28, 2024
June 28, 2024
Medincell joins the Euronext Tech Leaders
June 11, 2024
June 11, 2024
Medincell publishes its consolidated annual financial results
June 10, 2024
June 10, 2024
Publication of the financial results for the 2023-2024 fiscal year and videoconference on Monday, June 10, 2024
June 3, 2024
June 3, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
Update of the 2024 financial calendar
May 27, 2024
May 27, 2024
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company’s Latest News, Outlook, and R&D Activities
May 13, 2024
May 13, 2024
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
